CD19/CD22 CAR-T Cell Therapy for Children with MRD-Positive B-ALL

This study focuses on testing a new treatment called CAR-T cell therapy for children with a type of blood cancer known as B-lineage Acute Lymphoblastic Leukemia (B-ALL). Specifically, it targets those who still show signs of the disease after initial treatment, known as MRD-positive. The aim is to see if this treatment is safe and effective for these children, as current options might not fully eliminate cancer cells. Successful outcomes could lead to better treatment strategies for these young patients, potentially improving survival rates and quality of life. Participants in the study undergo a series of steps, starting with an initial screening to ensure they meet the criteria for treatment. After consenting, the child's own white blood cells are collected and modified in a lab to create CAR-T cells that target cancer cells. Before receiving the CAR-T cells through an intravenous infusion, participants undergo a preparatory treatment to reduce existing lymphocytes, using medications such as fludarabine and cyclophosphamide. The effectiveness of the treatment is assessed through tests measuring remaining cancer cells. Participants are closely monitored for side effects like CRS and ICANS, with follow-ups occurring frequently in the first month, gradually reducing to yearly check-ins over several years.